DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs.
Ohara M, Nagata T, Hara RI, Yoshida-Tanaka K, Toide N, Takagi K, Sato K, Takenaka T, Nakakariya M, Miyata K, Maeda Y, Toh K, Wada T, Yokota T.
Ohara M, et al. Among authors: maeda y.
Mol Ther Nucleic Acids. 2024 Jul 31;35(3):102289. doi: 10.1016/j.omtn.2024.102289. eCollection 2024 Sep 10.
Mol Ther Nucleic Acids. 2024.
PMID: 39252874
Free PMC article.